

# NCI Translational Science Meeting: Poster Presenter Assignments

(alphabetical order by presenter)

Presenter's First Name	Presenter's Last Name	Concurrent Session	Poster Discussion Session	Poster #	Room
Cory	Abate-shen	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	169	Pavilion 23
Alex	Adjei	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	198	Mezzanine 3
Jude	Alsarraj	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	39	Capital Club
Joshi	Alumkal	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	310	Pavilion 23
Paul	Amazeen	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Imaging for Cancer Detection, Staging, or Risk Stratification	85	Conference 6
Stefan	Ambs	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	206	Mezzanine 3
Panagiotis	Anastasiadis	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	368	Mezzanine 2
Judy	Anderson	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	256	Mezzanine 2
Karen	Anderson	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	225	Capital Club
Kenneth	Anderson	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	346	Capital Club
Michael	Andreeff	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	293	Junior Ballroom C
Michael	Andreeff	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	354	Mezzanine 2
Michael	Andreeff	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	170	Pavilion 23
Elliot	Androphy	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	171	Pavilion 23
Olga	Aprelikova	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	40	Capital Club
Farrukh	Aqil*	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	159	Conference 6
John	Araujo	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	172	Pavilion 23
Gustavo	Ayala	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	226	Capital Club
Nabeel	Bardeesy	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers: Modeling and Profiling	407	Conference 6
Deb	Barton	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	132	Junior Ballroom C
Jennifer	Barton	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Imaging for Cancer Detection, Staging, or Risk Stratification	86	Conference 6
Karen	Basen-Engquist	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	133	Junior Ballroom C
Rashid	Bashir	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	257	Mezzanine 2
Surinder	Batra	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	65	Pavilion 23
Daniel	Beauchamp	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	249	Capital Club
Tristan	Beaudette	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	98	Mezzanine 2
Steven	Belinsky	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	381	Pavilion 22
William	Benedict	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	99	Mezzanine 2
Gerold	Bepler	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	151	Conference 6
Nathan	Berger	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	134	Junior Ballroom C
P.S.	Bernard	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	428	Capital Club
Paul	Bertics	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	258	Mezzanine 2
Jay	Berzofsky	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	416	Mezzanine 3
William	Bigbee	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	259	Mezzanine 2
Oliver	Bogler	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	363	Mezzanine 2
Catherine	Bollard	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	294	Junior Ballroom C
Monica	Branco*	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	248	Capital Club

Russell	Broadus	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	251	Capital Club
J. Martin	Brown	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	355	Mezzanine 2
Richard	Bruce	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	271	Mezzanine 2
Francis	Brunicki	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	324	Pavilion 23
Donald	Buchsbam	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	325	Capital Club
Raphael	Bueno	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	231	Capital Club
Harvey	Bumpers	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	227	Capital Club
Angelika	Burger	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	31	Pavilion 22
John	Bushweller	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	332	Capital Club
Lisa	Butterfield	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	298	Junior Ballroom C
Paul	Cairns	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	64	Pavilion 23
Chris	Campbell	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	43	Capital Club
Jacek	Capala	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	284	Pavilion 22
Natasha	Caplen	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	340	Capital Club
William	Carroll	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	228	Capital Club
Kevin A.	Cassady	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	326	Capital Club
James	Cerhan	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	202	Mezzanine 3
Andrew	Chan	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	152	Conference 6
Wing	Chan	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	229	Capital Club
Wing	Chan	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	237	Capital Club
Albert	Chang	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	276	Pavilion 22
Jenny	Chang	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	4	Mezzanine 3
Alain	Charest	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers: Modeling and Profiling	393	Conference 6
Wei	Chen	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	174	Pavilion 23
Leo	Cheng	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	230	Capital Club
Yung-chi	Cheng	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	327	Capital Club
Durga Prasad	Cherukuri	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	66	Pavilion 23
John	Chevillet	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers: Modeling and Profiling	395	Conference 6
David	Chia	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	246	Capital Club
Arul	Chinnaiyan	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	81	Pavilion 23
Daniel	Cho	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	357	Mezzanine 2
Sherry	Chow	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	153	Conference 6
Curt	Civin	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	203	Mezzanine 3
Timothy	Clay	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	100	Mezzanine 2
Charles	Cleeland	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	135	Junior Ballroom C
Nicola	Clegg	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	308	Pavilion 23
Nancy	Colburn	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	167	Conference 6
Nancy	Colburn	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	149	Junior Ballroom C
Rebecca	Cook	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	24	Pavilion 22
Sarah	Cooley	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	295	Junior Ballroom C
Dan	Costa	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	35	Pavilion 22
W. Douglas	Cress	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	338	Capital Club
Rebecca	Crowley	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	426	Mezzanine 2

Marcia	Cruz Correa	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	376	Pavilion 22
Kevin	Cullen	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	388	Pavilion 22
Bogdan	Czerniak	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	51	Capital Club
Thao	Dang	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	182	Pavilion 23
Tirtha	Das	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	44	Capital Club
Ram	Datar	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	275	Mezzanine 2
Michael	Davies	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	45	Capital Club
Steven	Davis	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Advances in Device-Based Cancer Interventions	119	Junior Ballroom D
Steven	Davis	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	277	Pavilion 22
Chi-Ping	Day	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	358	Mezzanine 2
Waldemar	Debinski	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	408	Mezzanine 3
Wendy	Demark-Wahnefried	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	136	Junior Ballroom C
Phillip	Dennis	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	323	Capital Club
Paul	Dent	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	186	Pavilion 23
Mark	Dewhirst	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	278	Pavilion 22
Alan	Diamond	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	155	Conference 6
Dimiter	Dimitrov	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	176	Pavilion 23
James	DiRenzo	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	6	Mezzanine 3
Dirk	Dittmer	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	328	Capital Club
Jennifer	Doll	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers: Modeling and Profiling	396	Conference 6
Raymond	Dubois	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	156	Conference 6
Leisha	Emens	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	409	Mezzanine 3
Jennifer	Eng-Wong	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	309	Pavilion 23
Charles	Erlichman	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	26	Pavilion 22
Laura	Esserman	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	281	Pavilion 22
Laura	Esserman	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	232	Capital Club
Laura	Esserman	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	233	Capital Club
Andy	Evens	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	234	Capital Club
Mark	Evers	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	189	Pavilion 23
Carol	Fabian	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	378	Pavilion 22
Carol	Fabian	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	157	Conference 6
Marwan	Fakih	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	7	Mezzanine 3
Zhen	Fan	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	16	Mezzanine 3
Zhen	Fan	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	213	Mezzanine 3
Bingliang	Fang	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	333	Capital Club
Carolyn	Fang	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	137	Junior Ballroom C
Andrew	Feldman	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	46	Capital Club
William	Fenical	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	330	Capital Club
Daniel	Fernandes	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	349	Capital Club
Martin	Fernandez-Zapico	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	23	Pavilion 22
James L. M.	Ferrara	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	427	Junior Ballroom C
Soldano	Ferrone	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	102	Mezzanine 2
Paul	Fisher	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	113	Mezzanine 2

Edward	Flynn	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Imaging for Cancer Detection, Staging, or Risk Stratification	88	Conference 6
Eric	Ford	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Advances in Device-Based Cancer Interventions	120	Junior Ballroom D
Heide	Ford	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	317	Pavilion 23
Andres	Forero	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	360	Mezzanine 2
Markus	Frank	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	114	Mezzanine 2
Wilbur	Franklin	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	262	Mezzanine 2
Mitchell	Frederick*	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	27	Pavilion 22
Juan	Fueyo	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	331	Capital Club
Gary	Gallick	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	12	Mezzanine 3
Kalpana	Ghoshal	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	336	Capital Club
Parkash	Gill	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	361	Mezzanine 2
G. Yancey	Gillespie	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	366	Mezzanine 2
Theresa	Gillespie	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	138	Junior Ballroom C
Matthew	Goetz	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	28	Pavilion 22
Michael	Goggins	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	62	Capital Club
Amir	Goldkorn	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	255	Capital Club
Kathleen	Goss	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	181	Pavilion 23
Stephen	Gottschalk	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	306	Junior Ballroom C
James	Goydos	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	362	Mezzanine 2
Jennifer R.	Grandis*	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	25	Pavilion 22
Steven	Grant	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	3	Mezzanine 3
Steven	Grant	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	8	Mezzanine 3
Heidi	Greulich	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	29	Pavilion 22
Michael	Grever	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	263	Mezzanine 2
William	Grizzle	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	67	Pavilion 23
Clinton	Grubbs	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	158	Conference 6
Thomas	Guerrero	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	282	Pavilion 22
Daniel	Gustafson	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	207	Mezzanine 3
Daniel	Gustafson	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	30	Pavilion 22
Andrew	Haas	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	364	Mezzanine 2
Andrew	Haas	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	103	Mezzanine 2
Ruth	Halaban	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	219	Mezzanine 3
Paul	Haluska	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	178	Pavilion 23
James	Harbour	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	235	Capital Club
Nancy	Hardy	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	296	Junior Ballroom C
Lynn	Hartmann	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	312	Pavilion 23
Tayyaba	Hasan	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Advances in Device-Based Cancer Interventions	121	Junior Ballroom D
Tayyaba	Hasan	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	208	Mezzanine 3
Amy	Heimberger	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	9	Mezzanine 3
Amy	Heimberger	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	411	Mezzanine 3
Richard	Heller	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Advances in Device-Based Cancer Interventions	122	Junior Ballroom D
Richard	Heller	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	104	Mezzanine 2
Linda	Hendershot	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	200	Mezzanine 3

Barbara	Henderson	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Advances in Device-Based Cancer Interventions	125	Junior Ballroom D
Bryan	Hennessy	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	48	Capital Club
Bryan	Hennessy	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	49	Capital Club
Sunil	Hingorani	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	397	Mezzanine 2
Fred	Hirsch	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	383	Pavilion 22
James	Hodge	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	412	Mezzanine 3
Beata	Holkova	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	10	Mezzanine 3
David	Hong	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	365	Mezzanine 2
Hong-Ming	Hu	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	105	Mezzanine 2
Christene	Huang	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	101	Mezzanine 2
Jiaoti	Huang	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	55	Capital Club
Chien-Fu	Hung	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	106	Mezzanine 2
Mien-chie	Hung	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers: Modeling and Profiling	405	Conference 6
Mien-chie	Hung	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	356	Mezzanine 2
Shelley	Hwang	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	236	Capital Club
Bonnie	Hylander	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	334	Capital Club
John	Isaacs	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	175	Pavilion 23
Hiromichi	Ito	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	50	Capital Club
Samson	Jacob	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	11	Mezzanine 3
Elaine	Jaffe	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	238	Capital Club
Robert	Jenkins	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	239	Capital Club
Feng	Jiang	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	68	Pavilion 23
Yongkui	Jing	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	351	Capital Club
David	Jones	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	180	Pavilion 23
Pawel	Kalinski	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	117	Mezzanine 2
Daniel	Kamei	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Advances in Device-Based Cancer Interventions	123	Junior Ballroom D
Shalini	Kanekar	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	139	Junior Ballroom C
Philip	Kantoff	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	223	Mezzanine 3
Judith	Karp	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	335	Capital Club
Partow	Kebriaei	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	297	Junior Ballroom C
Robert	Keith	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	160	Conference 6
Mark	Kelley	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	359	Mezzanine 2
John	Kenten	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers: Modeling and Profiling	398	Conference 6
Ann	Killary	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	78	Pavilion 23
Alison	Klein	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	379	Pavilion 22
Ruth	Kleinerman	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	140	Junior Ballroom C
Carolyn	Klinge	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	211	Mezzanine 3
Jill	Kolesar	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	13	Mezzanine 3
Victoria	Korovkina	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	367	Mezzanine 2
Kenneth	Krohn	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	280	Pavilion 22
Jon	Kurie	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	197	Pavilion 23
Primo	Lara	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	84	Pavilion 23
Christina	Laukaitis	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	380	Pavilion 22

Josh	Lauring	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	177	Pavilion 23
Craig	Leach	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	337	Capital Club
Cynthia	LeBron*	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	14	Mezzanine 3
Ethan	Lee	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	192	Pavilion 23
Jeffrey E.	Lee	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	240	Capital Club
Philip	Lee	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Imaging for Cancer Detection, Staging, or Risk Stratification	89	Conference 6
Suzanne	Lentzsch	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	109	Mezzanine 2
Heinz-Josef	Lenz	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	224	Mezzanine 3
David	Levens	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	5	Mezzanine 3
Brian	Leyland-Jones	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	241	Capital Club
Steven	Lipshultz	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	161	Conference 6
Chunming	Liu	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	168	Conference 6
Susan	Lobo-Ruppert	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	205	Mezzanine 3
Albert	Lockhart	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	214	Mezzanine 3
Anna	Lokshin	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	70	Pavilion 23
Patricia	LoRusso	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	285	Pavilion 22
Youyong	Lu	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	243	Capital Club
Lawrence	Lum	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	415	Mezzanine 3
Ruth	Lupu	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	314	Pavilion 23
Susan	Lutgendorf	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	141	Junior Ballroom C
Kenji	Maeda	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	339	Capital Club
Daruka	Mahadevan	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	188	Pavilion 23
Ravindra	Majeti	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	17	Mezzanine 3
Ram	Mani	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	52	Capital Club
David	Mankoff	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	286	Pavilion 22
Jenny	Mao	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	382	Pavilion 22
Jenny	Mao	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	162	Conference 6
Li	Mao	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	369	Mezzanine 2
P. Kelly	Marcom	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	215	Mezzanine 3
Lawrence	Marks	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	287	Pavilion 22
Otoniel	Martinez-Maza	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	69	Pavilion 23
Pierre	Massion	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	387	Pavilion 22
J. Michael	Mathis	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	307	Pavilion 23
William	Matsui	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	18	Mezzanine 3
Ryan	Mattison*	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	283	Pavilion 22
David	McConkey	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	195	Pavilion 23
Michael	McGrath	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers: Modeling and Profiling	399	Conference 6
Robert	McWilliams	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	142	Junior Ballroom C
Dan	Mercola	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	209	Mezzanine 3
Soheil	Meshinchi	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	244	Capital Club
Raymond	Meyn	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	32	Pavilion 22
Kevin	Mills	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	266	Mezzanine 2
Martha	Mims	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	260	Mezzanine 2

Zoe	Miner	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	71	Pavilion 23
Duane	Mitchell	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	300	Junior Ballroom C
Edna	Mora	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	370	Mezzanine 2
Meredith	Morgan	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	184	Pavilion 23
Yuriko	Mori	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	72	Pavilion 23
John	Morris	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	315	Pavilion 23
Lindsay	Morton	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	245	Capital Club
Christopher	Moskaluk	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	268	Mezzanine 2
Lorelei	Mucci	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	384	Pavilion 22
Lorelei	Mucci	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	143	Junior Ballroom C
Kate	Nathanson	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	56	Capital Club
Robert	Negrin	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	301	Junior Ballroom C
Barry	Nelkin	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	183	Pavilion 23
Peter	Nelson	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	311	Pavilion 23
William	Nelson	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	19	Mezzanine 3
Shuming	Nie	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	279	Pavilion 22
Shuming	Nie	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	264	Mezzanine 2
Jorge	Nieva	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	265	Mezzanine 2
Barbara	Norquist	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	216	Mezzanine 3
James	Norris	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	341	Capital Club
Mukesh	Nyati	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	199	Mezzanine 3
Mukesh	Nyati	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	22	Pavilion 22
Barry	O'Keefe	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	322	Capital Club
Olufunmilayo I.	Olopade*	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	389	Pavilion 22
Frank	Ondrey	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	77	Pavilion 23
Jimmy	Orjala	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	342	Capital Club
Patrick	Ott	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	371	Mezzanine 2
Sara	Pai	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	73	Pavilion 23
Koon	Pak	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Imaging for Cancer Detection, Staging, or Risk Stratification	87	Conference 6
William	Pao	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	217	Mezzanine 3
William	Pao	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	33	Pavilion 22
Nickolas	Papadopoulos	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers: Modeling and Profiling	401	Conference 6
William	Parker	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	343	Capital Club
Ian	Parney	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	111	Mezzanine 2
Michael	Pashley	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Imaging for Cancer Detection, Staging, or Risk Stratification	93	Conference 6
Kah-Whye	Peng	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	288	Pavilion 22
Matt	Petroski	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	193	Pavilion 23
Shari	Pilon-Thomas	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	108	Mezzanine 2
stephen	Plymate	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	58	Capital Club
Eckhard	Podack	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	112	Mezzanine 2
Pamela	Pollock	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	173	Pavilion 23
Pamela	Pollock	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	42	Capital Club
Richard	Posner	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	344	Capital Club

Tayebeh	Pourmotabbed	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	372	Mezzanine 2
Ganapathy	Prasad	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	386	Pavilion 22
Michael	Prystowsky	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	242	Capital Club
Vinay	Puduvalli	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	345	Capital Club
Suresh	Ramalingam	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	57	Capital Club
Nilsa	Ramirez	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	269	Mezzanine 2
C.V.	Rao	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	418	Mezzanine 3
Chinthalapally V.	Rao	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	34	Pavilion 22
Fred	Regnier	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	76	Pavilion 23
Michael	Rettig	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	289	Pavilion 22
Antoni	Ribas	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	303	Junior Ballroom C
Thomas	Ried	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	347	Capital Club
John	Risinger	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	210	Mezzanine 3
William	Rom	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Imaging for Cancer Detection, Staging, or Risk Stratification	90	Conference 6
Marjorie	Romkes	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	201	Mezzanine 3
Daniel	Rosenberg	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	163	Conference 6
Daniel	Rosenberg	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Imaging for Cancer Detection, Staging, or Risk Stratification	92	Conference 6
Michael	Roth	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	187	Pavilion 23
Hemant	Roy	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Imaging for Cancer Detection, Staging, or Risk Stratification	94	Conference 6
Pierre	Saintigny	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	247	Capital Club
John	Sampson	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	304	Junior Ballroom C
Barbara	Savoldo	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	305	Junior Ballroom C
David	Scheinberg	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	372B	Mezzanine 2
David	Scheinberg	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	425	Mezzanine 3
Randy	Scherer	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	290	Pavilion 22
Richard	Schilsky	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	218	Mezzanine 3
Eva	Schmelz	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	20	Mezzanine 3
Joel	Schneider	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Advances in Device-Based Cancer Interventions	126	Junior Ballroom D
Natalie	Scholler	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Imaging for Cancer Detection, Staging, or Risk Stratification	95	Conference 6
Nathalie	Scholler	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	420	Mezzanine 3
David	Schwartz	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Advances in Device-Based Cancer Interventions	127	Junior Ballroom D
Marc	Schwartz	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	145	Junior Ballroom C
Robert	Seeger	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	115	Mezzanine 2
Eva	Sevick-Muraca	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Advances in Device-Based Cancer Interventions	128	Junior Ballroom D
Geoffrey	Shapiro	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	179	Pavilion 23
Robert	Sharkey	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	421	Mezzanine 3
Dong	Shin	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	150	Conference 6
Jill	Siegfried	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	319	Pavilion 23
Sabina	Signoretti	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	41	Capital Club
Shivendra	Singh	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	165	Conference 6
Dorothy	Sipkins	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	154	Mezzanine 2
Alphonse	Sirica	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	36	Pavilion 22
Steven	Skates	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	79	Pavilion 23



Larry	Sklar	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	348	Capital Club
Jeffrey	Smith	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	377	Pavilion 22
Anil	Sood	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	375	Pavilion 22
Anil	Sood	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	414	Mezzanine 3
David	Spencer	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Adoptive Cellular Therapies	299	Junior Ballroom C
John	Stewart	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	350	Capital Club
Alexander	Stoeck	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	190	Pavilion 23
Gary	Swan	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	146	Junior Ballroom C
Karen	Syrjala	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	292	Pavilion 22
Zoltan	Szallasi	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	212	Mezzanine 3
Michael	Tainsky	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	80	Pavilion 23
Ming	Tan	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	329	Capital Club
Michael	Tangrea	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers: Modeling and Profiling	403	Conference 6
Clare	Tempany	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Advances in Device-Based Cancer Interventions	129	Junior Ballroom D
Premal	Thaker	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	191	Pavilion 23
Premal	Thaker	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	59	Capital Club
C. Shad	Thaxton*	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Advances in Device-Based Cancer Interventions	124	Junior Ballroom D
Dan	Theodorescu	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	316	Pavilion 23
Dan	Theodorescu	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	267	Mezzanine 2
Carol	Thiele	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	15	Mezzanine 3
Patricia	Thompson	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	164	Conference 6
Patricia	Thompson	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Imaging for Cancer Detection, Staging, or Risk Stratification	96	Conference 6
David	Threadgill	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	37	Pavilion 22
Javier	Torres-Roca	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	220	Mezzanine 3
Timothy	Triche	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers: Modeling and Profiling	404	Conference 6
Cornelia	Trimble	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	221	Mezzanine 3
Cornelia	Trimble	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	116	Mezzanine 2
Melissa	Troester	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	61	Capital Club
Jashim	Uddin*	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Imaging for Cancer Detection, Staging, or Risk Stratification	97	Conference 6
Elizabeth	Unger	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	75	Pavilion 23
Armando	Valdez	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	147	Junior Ballroom C
Michael	Velec	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Advances in Device-Based Cancer Interventions	130	Junior Ballroom D
Amit	Verma	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers: Modeling and Profiling	394	Conference 6
Robert	Vonderheide	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	422	Mezzanine 3
Lalage	Wakefield	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	373	Mezzanine 2
Tza-huei	Wang	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	272	Mezzanine 2
Zhou	Wang	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	320	Pavilion 23
Qianli	Wang*	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	410	Mezzanine 3
James	Waschek	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	185	Pavilion 23
James	Waschek	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	54	Capital Club
Mark	Watson	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	273	Mezzanine 2
Sheng	Wei	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	352	Capital Club
Wei-zen	Wei	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	107	Mezzanine 2

Ralph	Weichselbaum	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Targeting Angiogenesis and the Tumor Microenvironment	374	Mezzanine 2
Louis	Weiner	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Targeting the EGFR Family	38	Pavilion 22
Louis	Weiner	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	423	Mezzanine 3
Jonathan	Weiss	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	424	Mezzanine 3
William	Weiss	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	194	Pavilion 23
Robert	Wenham	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	274	Mezzanine 2
Lari	Wenzel	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Impact of Stress and Physical Activity on Cancer	148	Junior Ballroom C
Trey	Westbrook	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	318	Pavilion 23
Christopher	Whelan	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	82	Pavilion 23
Theresa	Whiteside	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Vaccines for Cancer Treatment and Prevention	118	Mezzanine 2
Samuel	Wickline	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Imaging to Guide Cancer Therapy	291	Pavilion 22
David	Wink	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Targeting Signaling Pathways	196	Pavilion 23
Kwong-Kwok	Wong	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	252	Capital Club
Scott	Wong	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Therapeutic Antibodies and Combination Therapies	417	Mezzanine 3
Stuart	Wong	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Advances in Device-Based Cancer Interventions	131	Junior Ballroom D
Stuart	Wong	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Chemoprevention	166	Conference 6
Savio	Woo	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Identification and Credentialing of Novel Agents and Combinations	353	Capital Club
Frank	Worden	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	253	Capital Club
Margaret	Wrensch	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	390	Pavilion 22
Xifeng	Wu	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	391	Pavilion 22
Xifeng	Wu	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	204	Mezzanine 3
Xifeng	Wu	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Markers to Personalize Treatment	222	Mezzanine 3
George	Xu	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	254	Capital Club
Haining	Yang	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	83	Pavilion 23
Rose	Yang	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers for Risk Stratification and Prevention	392	Pavilion 22
Nelson	Yee	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	21	Mezzanine 3
Srinivasan	Yegnasubramanian	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Biomarkers: Modeling and Profiling	406	Conference 6
Jen Jen	Yeh	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	Molecular and Cellular Prognostic Markers	250	Capital Club
Anas	Younes	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	47	Capital Club
Maciej	Zborowski	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Cancer Stem Cells and Epigenomics	1	Mezzanine 3
Martha	Zeiger	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	Biomarkers for Early Detection	74	Pavilion 23
Rugang	Zhang	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	53	Capital Club
John	Zhong	Concurrent Session 2 - Thursday, November 5, 3:30-6:30 p.m.	New Approaches to Biospecimens and Detection	261	Mezzanine 2
Tong	Zhou	Concurrent Session 3 - Friday, November 6, 8-11 a.m.	Agents for Hormonally Driven Cancers	321	Pavilion 23
Wei	Zhou	Concurrent Session 1 - Thursday, November 5, 11 a.m.-3 p.m.	The Biomarker Horizon: Pathways and Targets of Interest	63	Capital Club

\* Replacement presenter.